> Johnson & Johnson's ($JNJ) Janssen unit submitted an application for expanded European approval of its blood cancer drug Imbruvica, as a therapy for previously untreated patients with chronic lymphocytic leukemia. Release
> These days, it's common to see several drugs racing for a first-in-class approval, which means that small accelerations in R&D can yield big payoffs, a Tufts University study found. Report
> Johnson & Johnson and GlaxoSmithKline's ($GSK) ViiV Healthcare joint venture touted data from Phase II studies of two long-acting injectable versions of now-daily HIV pills. Release | Report
And Finally ... Mylan ($MYL) won U.S. antitrust approval to buy Perrigo ($PRGO), provided it sells off rights to several generic products. Release